arrow_back Back to App

Enhanced Transparency: Drug Origin and Supply Chain Information

New rules aim to increase information about where drugs and their ingredients come from. This will give citizens better insight into the drug supply chain, potentially impacting their safety and trust in pharmaceutical products. Companies will need to report production and supplier data more frequently.
Key points
Pharmaceutical companies must report more frequently on the origin of ingredients used in drug manufacturing.
Drug labels and accompanying documents will include information about the original manufacturer of active pharmaceutical ingredients.
The goal is to enhance transparency and safety of drugs available on the market.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3810
Sponsor: Rep. Eshoo, Anna G. [D-CA-16]
Process start date: 2023-06-05
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug Origin Transparency Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3810.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-05.

What are the main provisions?

Key points include:

  • Pharmaceutical companies must report more frequently on the origin of ingredients used in drug manufacturing.
  • Drug labels and accompanying documents will include information about the original manufacturer of active pharmaceutical ingredients.
  • The goal is to enhance transparency and safety of drugs available on the market.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Eshoo, Anna G. [D-CA-16].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health